United Therapeutics (UTHR) Capital Expenditures Growth (1y) (2010 - 2026)
United Therapeutics (UTHR) Capital Expenditures Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -21.54% |
| 10 | Vireo Growth | 10.52 Bn | 10.37 Bn | 59.30 Mn | 881.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.98% |
| Dec 31, 2025 | -366.78% |
| Sep 30, 2025 | 267.84% |
| Jun 30, 2025 | -114.57% |
| Mar 31, 2025 | 217.37% |
| Dec 31, 2024 | 628.66% |
| Sep 30, 2024 | 249.41% |
| Jun 30, 2024 | -11.69% |
| Mar 31, 2024 | 28.26% |
| Dec 31, 2023 | -2,442.86% |
| Sep 30, 2023 | -206.59% |
| Jun 30, 2023 | 297.65% |
| Mar 31, 2023 | 36.30% |
| Dec 31, 2022 | -99.01% |
| Sep 30, 2022 | -135.61% |
| Jun 30, 2022 | 1,044.44% |
| Mar 31, 2022 | 164.71% |
| Dec 31, 2021 | 28.60% |
| Sep 30, 2021 | 275.00% |
| Jun 30, 2021 | -109.89% |